openPR Logo
Press release

Metformin Hydrochloride API Market to Expand at a CAGR of ~5% from 2021 to 2031

07-04-2022 06:34 AM CET | Health & Medicine

Press release from: Transparency Market Research

Metformin Hydrochloride API Market: Introduction

According to the report, the global metformin hydrochloride API market was valued at ~US$ 300 Mn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031. Metformin hydrochloride is primarily used in the treatment of diabetes. The prevalence of diabetes is expected to increase across the world due to change in lifestyle and factors such as malnutrition and genetic mutations. According to government and private organizations operating in the diabetes industry, diabetes is considered one of the top fatal diseases globally. According to the American Diabetes Association, diabetes accounts for around 71,000 deaths in the U.S. each year.
Diabetes is more prevalent in the geriatric population. According to the American Diabetes Association, over 25% of the diabetic patients in the U.S. are aged 65 years and above.

North America held a major share of the global metformin hydrochloride API market in 2020 due to high procurement of metformin hydrochloride API by pharmaceutical companies and contract manufacturing organizations in the region. The metformin hydrochloride API market in Asia Pacific is expected to expand at high CAGR of 6.9% from 2021 to 2031.

Report Overview: https://www.transparencymarketresearch.com/metformin-hydrochloride-api-market.html

Rise in Prevalence of Diabetes to Drive Market
The rise in prevalence of diabetes is projected to drive the global metformin hydrochloride API market during the forecast period. Diabetes is a critical long-term condition with a major impact on the lives and well-being of individuals across the world. It is among the top 10 causes of death in adults, and was estimated to have caused 4.2 million deaths globally in 2019. According to the International Diabetes Federation, the global prevalence of diabetes was 9.3% (463 million people) in 2019 and expected to reach 10.2% (578 million people) by 2030 and 10.9% (700 million people) by 2045.

High income countries have higher prevalence of diabetes i.e., 10.4% compared to low-income countries at 4.0%. Around 374 million people are at increased risk of developing type 2 diabetes.

Metformin Hydrochloride to Dominate Global Market

In terms of product, the global metformin hydrochloride API market has been classified into metformin hydrochloride, metformin hydrochloride DC, and others. The metformin hydrochloride segment dominated the global metformin hydrochloride API market in 2020, and the trend is anticipated to continue during the forecast period. The segment is likely to dominate the market due to high consumption of metformin hydrochloride by pharmaceutical companies and availability of products in the market.

Request A Sample: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=82470

Pharmaceutical Companies Held Major Share of Metformin Hydrochloride API Market
Based on end user, the global metformin hydrochloride API market has been categorized into pharmaceutical companies, contract research organizations, and others. The pharmaceutical companies segment held a major share of the global metformin hydrochloride API market in 2020. The pharmaceutical companies dominance can be attributed to increase in production of metformin hydrochloride drugs, rise in R&D, and presence of a large number of pharmaceutical companies.

Extended Release Tablet to be Preferred
In terms of dosage form, the global metformin hydrochloride API market has been divided into tablet, extended release tablet, and oral solution. The segment's dominance can be attributed to the benefits offered by extended release tablets such as reduced frequency of dosage over other dosage forms.

North America to Lead Global Market; Asia Pacific to Offer Significant Opportunities
In terms of region, the global metformin hydrochloride API market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global metformin hydrochloride API market during the forecast period. High prevalence of diabetes and increase in geriatric population are anticipated to drive the market in the region. According to the CDC, nearly 34.2 million people have diabetes (10.5% of the population) and around 88 million people above 18 years have prediabetes (34.5% of the adult population) in the U.S. The market in Europe is expected to expand at a high CAGR in the near future, owing to the presence of local as well as global players and increase in the demand for metformin hydrochloride API in the region.

The metformin hydrochloride API market in Asia Pacific is likely to grow at a rapid pace in the near future. Rise in awareness and increase in healthcare expenditure in the region are projected to propel the market in Asia Pacific over the next few years.

Request for covid19 Impact Analysis:
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=82470

Growth Strategies of Key Players
Key players operating in the global metformin hydrochloride API market are Auro Laboratories Limited, Abhilasha Pharma Pvt. Ltd., Stanex Drugs & Chemicals Pvt. Ltd., Fengchen Group Co., Ltd., NS Chemicals, Midas Pharma GmbH, Harman Finochem Ltd., Aarti Drugs Ltd., Bayer AG, Ipca Laboratories Ltd., Panacea Biotech Ltd., Aristopharma Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Intas Pharmaceuticals Ltd., Bal Pharma Limited, Sohan Healthcare Pvt. Ltd., JD Chem (I), Kothari Phytochemicals & Industries Ltd., Turtle Pharma Private Limited, Shijiazhuang Polee Pharmaceutical Co., Ltd., Shouguang Fukang Pharmaceutical Co., Ltd., USV Private Limited, Exemed Pharmaceuticals, Farmhispania Group, Shandong Keyuan Pharmaceutical Co., Ltd. Merck KGaA, Taj API, Vistin Pharma AS, and Wanbury Limited.

These companies adopt the strategy of capacity expansion in order to expand market share. For instance, in November 2020, Aarti Drugs Ltd.

announced plans to expand the metformin hydrochloride API manufacturing capacity to 3,000 TPM. The company will start the phase I expansion project to 2,000 TPM in FY20-21.

• Metformin Hydrochloride API Market, by End User
o Pharmaceutical Companies
o Contract Research Organizations
o Others

More Trending Reports by Transparency Market Research:

Liquid Filled Hard Capsules Market: https://www.transparencymarketresearch.com/liquidfilled-hard-capsules-market.html

Antihypertensive Drugs Market: https://www.transparencymarketresearch.com/antihypertensive-drugs-market.html

Controlled Substance Market: https://www.transparencymarketresearch.com/us-controlled-substance-market.html

Surgical Site Infections Market: https://www.transparencymarketresearch.com/surgical-site-infections-market.html

Tablet Coatings Market: https://www.transparencymarketresearch.com/tablet-coatings-market.html

Tree Nut Allergy Market: https://www.transparencymarketresearch.com/us-tree-nut-allergy-market.html

Cannabinoids Market: https://www.transparencymarketresearch.com/cannabinoids-market.html

Meningococcal Vaccines Market: https://www.transparencymarketresearch.com/meningococcal-vaccines-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.

Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Metformin Hydrochloride API Market to Expand at a CAGR of ~5% from 2021 to 2031 here

News-ID: 2669930 • Views: 142

More Releases from Transparency Market Research

Paperboard Packaging Market Compelling Long-Term Growth Story for the forecast y …
The growth of paperboard packaging market is witnessing steady growth of sales from growing utilization of this versatile material in multiple end-use industries. Revenues in paper and paperboard food packaging have grown remarkably on the back of the need for sturdy, lightweight, and printable-friendly packaging materials. The global paperboard packaging market is projected to reach valuation of US$ 299.4 Mn by 2031. Access Complete Report of Paperboard Packaging Market @ https://www.transparencymarketresearch.com/paperboard-market.html Enormous
On-the-Go Breakfast Packaging Market Size, Business Revenue Forecast, Leading Co …
Transparency Market Research (TMR) provides key valuable insights into the on-the-go breakfast packaging market in its published report, which incorporates global industry analysis, size, share, growth, opportunities, trends, and forecast for 2021-2029. In terms of revenue, the global market is anticipated to expand 1.6 times of current market value by the end of 2029, due to increasing demand for flexible packaging across several countries, about which TMR offers detailed insights
Interleaving Papers Market Industry Growth Situation and Prospects Research 2028
Smooth or fine surface finish not only adds to the aesthetics of a product but also enables the product manufacturer to claim for a higher price and still achieve consumer satisfaction. To make very fine surface finish, high investment on processing machinery is required. Further, this finish can be easily deteriorated by physical shocks experienced during transportation or handling of the product in bulk. Thus, interleaving papers play a crucial
Lamination Films Market Key Players and Production Information analysis with For …
Transparency Market Research (TMR) provides key valuable insights into the lamination films market in its published report, which incorporate global industry analysis, size, share, growth, opportunities, trends, and forecast for 2021-2029. In terms of revenue, the global market is anticipated to expand 1.6 times of current market value, by the end of 2029, considering to increasing demand for flexible packaging across several countries, about which TMR offers detailed insights and

All 5 Releases


More Releases for API

Terminating Twitter API Integrations
Thexyz Inc, the leading private email service that protects people and their data announces that a Twitter authentication apps developed by Thexyz will be discontinued and no longer supported. Thexyz focuses on security, privacy, freedom, and an open internet that respects the rights of individuals. It is a goal to work with organizations that share these values and discontinue support for services that do not. Thexyz has developed applications
Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles.   Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform.   Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The